TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com

Posted by on Apr 10th, 2025

Investment analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ:TXMD traded down $0.04 during midday trading on Thursday, reaching $0.85. The stock had a trading volume of 16,719 shares, compared to its average volume of 152,181. The firm has a fifty day simple moving average of $0.93 and a two-hundred day simple moving average of $1.20. TherapeuticsMD has a 12-month low of $0.70 and a 12-month high of $2.44.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.

Featured Articles

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.